SEARCH

SEARCH BY CITATION

References

  • 1
    Miller G. Epstein Barr Virus. Biology, pathogenesis, and medical aspects. In: FieldsBN, KnipeDM, eds. Virology. New York : Raven Press Ltd., 1990: 1921.
  • 2
    Rickinson AB, Moss DJ. Human cytotoxic T lymphocytes responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405431.
  • 3
    Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant 1998; 2: 5663.
  • 4
    Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280287.
  • 5
    Cacciarelli TV, Green M, Jaffe R et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66: 10471052.
  • 6
    Younes BS, McDiarmid SV, Martin MG et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 9499.
  • 7
    McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 16041611.
  • 8
    Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 13441349.
  • 9
    Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97103.
  • 10
    Porcu P, Eisenbeis CF, Pelletier RP et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood 2002; 100: 23412348.
  • 11
    Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 15491555.
  • 12
    Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551555.
  • 13
    Berney T, Delis S, Kato T et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002; 74: 10001006.
  • 14
    Dotti G, Rambaldi A, Fiocchi R et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86: 618623.
  • 15
    Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 11651171.
  • 16
    Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 39793981.
  • 17
    Baldanti F, Grossi P, Furione M et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000; 38: 613619.
  • 18
    Green M, Bueno J, Rowe D et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000; 70: 593596.
  • 19
    Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol 1999; 37: 11131116.
  • 20
    Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 12111216.
  • 21
    Lin JC, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 1984; 50: 5055.
  • 22
    Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848852.
  • 23
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995; 9: 5359.
  • 24
    Sokal EM, Caragiozoglou T, Lamy M, Reding R, Otte JB. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56: 13941398.
  • 25
    Callan MF, Tan L, Annels N et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998; 187: 13951402.
  • 26
    Praghakaran K, Wise B, Chen A, Schwarz K, Colombani P. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999; 34: 112116.